剖宫产术后药物性血栓预防指南推荐人群的静脉血栓栓塞发生率
该回顾性队列研究利用美国全国再入院数据库2015年10月至2017年12月数据,分析1 235 149例剖宫产患者。根据2011 ACOG、2012 ACCP、2015 RCOG和2018 ASH指南进行风险分层,发现推荐药物性预防的比例从0.2%(2018 ASH)到73.4%(2015 RCOG)不等,高危组VTE发生率从2.5/1000(2015 RCOG)到35.2/1000(2018 ASH)不等。
要点
- 不同指南推荐药物性VTE预防的剖宫产患者比例差异巨大(0.2%-73.4%)。
- 高危组VTE发生率因指南而异,从2.5/1000到35.2/1000。
- 产后330天VTE总发生率为2.1/1000(95%CI 2.0-2.2)。
核心结论
- 应用不同风险分层指南识别出的剖宫产术后VTE高风险人群比例差异很大,影响高危分类。
研究设计与样本
- 回顾性队列研究,使用美国全国再入院数据库2015年10月至2017年12月数据,共纳入1 235 149例剖宫产分娩。
主要发现
- 产后330天VTE发生率为2.1/1000(95%CI 2.0-2.2)。
- 推荐药物性预防的比例从0.2%(2018 ASH)到73.4%(2015 RCOG)。
- 高危组VTE发生率从35.2/1000(2018 ASH)到2.5/1000(2015 RCOG)。
关键数值与推荐
- 2011 ACOG、2012 ACCP、2015 RCOG和2018 ASH指南用于风险分层。
- VTE发生率基于诊断和操作代码识别。
临床怎么用
- 临床医生应了解不同指南推荐预防的差异,根据患者个体风险选择合适指南。
局限性
- 回顾性研究依赖行政数据编码,可能存在漏诊或错分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple guidelines regarding risk stratification for venous thromboembolism (VTE) incidence following cesarean delivery have been promulgated. OBJECTIVE: To estimate the percentage of cesarean delivery patients for which pharmacologic VTE would be recommended and subsequent incidence of VTE, based on several guidelines. PATIENTS/METHODS: This retrospective cohort study used data from the Nationwide Readmissions Database from October 2015 through December 2017. Diagnosis and procedure codes were used to identify patients undergoing cesarean delivery, incidence of VTE, and risk factors used to stratify risk in the existing guidelines. Time-to-event analysis was used to analyze data, stratified by risk categorization in 2011 American College of Obstetricians and Gynecologists (ACOG), 2012 American College of Chest Physicians (ACCP), 2015 Royal College of Obstetricians and Gynaecologists (RCOG), and 2018 American Society of Hematology (ASH) guidelines. RESULTS/CONCLUSIONS: In a cohort of 1 235 149 cesarean deliveries, VTE incidence was 2.1 per 1000 deliveries at 330 days following delivery (95% confidence interval: 2.0-2.2). Proportions of patients that would be recommended for pharmacologic prophylaxis ranged from 0.2% in 2018 ASH guidelines to 73.4% in 2015 RCOG criteria. Among groups considered at elevated risk for VTE for which pharmacologic prophylaxis would be recommended, VTE incidence varied from 35.2 per 1000 deliveries based on 2018 ASH criteria to 2.5 per 1000 in 2015 RCOG criteria. In a large cohort of cesarean deliveries in the United States, application of different risk stratification guidelines identified widely different proportions at risk of VTE following delivery, with implications for being categorized as having elevated risk.
引用
- Federspiel JJ, Wein LE, Addae-Konadu KL, et al. Venous thromboembolism incidence among patients recommended for pharmacologic thromboembolism prophylaxis after cesarean delivery in selected guidelines. J Thromb Haemost. 2021. PMID: 33345404. doi:10.1111/jth.15218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。